BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34506029)

  • 21. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
    García-Foncillas J; Díaz-Rubio E
    Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome.
    Poultsides GA; Bao F; Servais EL; Hernandez-Boussard T; DeMatteo RP; Allen PJ; Fong Y; Kemeny NE; Saltz LB; Klimstra DS; Jarnagin WR; Shia J; D'Angelica MI
    Ann Surg Oncol; 2012 Sep; 19(9):2797-804. PubMed ID: 22476753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
    Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN
    Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases.
    Satake H; Hashida H; Tanioka H; Miyake Y; Yoshioka S; Watanabe T; Matsuura M; Kyogoku T; Inukai M; Kotake T; Okita Y; Matsumoto T; Yasui H; Kotaka M; Kato T; Kaihara S; Tsuji A
    Oncologist; 2021 Jul; 26(7):e1125-e1132. PubMed ID: 33977607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
    DʼAngelica MI; Correa-Gallego C; Paty PB; Cercek A; Gewirtz AN; Chou JF; Capanu M; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N
    Ann Surg; 2015 Feb; 261(2):353-60. PubMed ID: 24646562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OncoSurge: a strategy for long-term survival in metastatic colorectal cancer.
    Alberts S; Poston G
    Colorectal Dis; 2003 Nov; 5 Suppl 3():20-8. PubMed ID: 23573557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sub-millimeter surgical margin is acceptable in patients with good tumor biology after liver resection for colorectal liver metastases.
    Xu D; Wang HW; Yan XL; Li J; Wang K; Xing BC
    Eur J Surg Oncol; 2019 Sep; 45(9):1551-1558. PubMed ID: 30879931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interactions of multiple gene alterations in colorectal liver metastases.
    Kawaguchi Y; Velasco JD; Arvide EM; Wei SH; Vauthey JN
    Chin Clin Oncol; 2019 Oct; 8(5):50. PubMed ID: 31500427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases.
    Nishioka Y; Chun YS; Overman MJ; Cao HST; Tzeng CD; Mason MC; Kopetz SW; Bauer TW; Vauthey JN; Newhook TE;
    J Am Coll Surg; 2022 Apr; 234(4):474-483. PubMed ID: 35290266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to preoperative chemotherapy: impact of change in total burden score and mutational tumor status on prognosis of patients undergoing resection for colorectal liver metastases.
    Ruzzenente A; Bagante F; Ratti F; Beal EW; Alexandrescu S; Merath K; Makris EA; Poultsides GA; Margonis GA; Weiss MJ; Popescu I; Aldrighetti L; Guglielmi A; Pawlik TM
    HPB (Oxford); 2019 Sep; 21(9):1230-1239. PubMed ID: 30792047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
    Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Impact of Adjuvant Chemotherapy after Hepatic Resection for Synchronous and Early Metachronous Colorectal Liver Metastases.
    Nishioka Y; Moriyama J; Matoba S; Kuroyanagi H; Hashimoto M; Shindoh J
    Dig Surg; 2018; 35(3):187-195. PubMed ID: 28848205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases?
    Adam R; Bhangui P; Poston G; Mirza D; Nuzzo G; Barroso E; Ijzermans J; Hubert C; Ruers T; Capussotti L; Ouellet JF; Laurent C; Cugat E; Colombo PE; Milicevic M
    Ann Surg; 2010 Nov; 252(5):774-87. PubMed ID: 21037433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is complete liver resection without resection of synchronous lung metastases justified?
    Mise Y; Kopetz S; Mehran RJ; Aloia TA; Conrad C; Brudvik KW; Taggart MW; Vauthey JN
    Ann Surg Oncol; 2015 May; 22(5):1585-92. PubMed ID: 25373535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases.
    Brudvik KW; Mise Y; Chung MH; Chun YS; Kopetz SE; Passot G; Conrad C; Maru DM; Aloia TA; Vauthey JN
    Ann Surg Oncol; 2016 Aug; 23(8):2635-43. PubMed ID: 27016292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
    Liu JH; Hsieh YY; Chen WS; Hsu YN; Chau GY; Teng HW; King KL; Lin TC; Tzeng CH; Lin JK
    Int J Colorectal Dis; 2010 Oct; 25(10):1243-9. PubMed ID: 20574727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
    Pak LM; Kemeny NE; Capanu M; Chou JF; Boucher T; Cercek A; Balachandran VP; Kingham TP; Allen PJ; DeMatteo RP; Jarnagin WR; D'Angelica MI
    J Surg Oncol; 2018 Mar; 117(4):634-643. PubMed ID: 29165816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Type of response to conversion chemotherapy strongly impacts survival after hepatectomy for initially unresectable colorectal liver metastases.
    Zimmitti G; Panettieri E; Ardito F; Rosso E; Mele C; Nuzzo G; Giuliante F
    ANZ J Surg; 2020 Apr; 90(4):558-563. PubMed ID: 31927783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancer.
    Thomay AA; Nagorney DM; Cohen SJ; Sigurdson ER; Truty MJ; Burtness B; Hall MJ; Chun YS
    J Gastrointest Surg; 2014 Jan; 18(1):69-74. PubMed ID: 24002765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.